Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dimopoulos, M. A.
Right arrow Articles by Alexanian, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimopoulos, M. A.
Right arrow Articles by Alexanian, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:288-289, 1994
© 1994 European Society for Medical Oncology

other

2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine

M. A. Dimopoulos, D. M. Weber, H. Kantarjian, M. Keating and R. Alexanian

Department of Hematology, University of Texas, M.D. Anderson Cancer Center Houston TX, U.S

Correspondence to: Meletios A. Dimopoulos, M.D., Department of Hematology, Box 1, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, U.S.A.

BACKGROUND: Fludarabine monophosphate and 2Chlorodeoxyadenosine are nucleoside analogues with activity against Waldenström macroglobulinemia. However, it is not clear whether prior exposure to one analogue precludes response to the other compound.

PATIENTS AND METHODS: Fourteen patients with Waldenström's macroglobulinemia and prior exposure to fludarabine were treated with two courses of 2chlorodeoxyadenosine.

RESULTS: Three out of four patients that had previously responded to fludarabine and were relapsing from unmaintained remission, achieved a partial response with 2chlorodeoxyadenosine therapy. However, only one out of 10 patients with disease resistant to fludarabine responded to 2chlorodeoxyadenosine.

CONCLUSIONS: 2chlorodeoxyadenosine may be effective in patients with Waldenström macroglobulinemia sensitive to fludarabine. However, this compound has limited activity for patients with disease resistant to fludarabine.

Waldenström macroglobulinemia, 2Chlorodeoxyadenosine, fludarabine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
A. Vijay and M. A. Gertz
Waldenstrom macroglobulinemia
Blood, June 15, 2007; 109(12): 5096 - 5103.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol., March 1, 2005; 23(7): 1564 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. I. Chen
Treatment for Waldenstrom's macroglobulinemia
Ann. Onc., April 1, 2004; 15(4): 550 - 558.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. V. Dhodapkar, J. L. Jacobson, M. A. Gertz, S. E. Rivkin, G. D. Roodman, J. M. Tuscano, M. Shurafa, R. A. Kyle, J. J. Crowley, and B. Barlogie
Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)
Blood, July 1, 2001; 98(1): 41 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, P. Panayiotidis, L. A. Moulopoulos, P. Sfikakis, and M. Dalakas
Waldenstrom’s Macroglobulinemia: Clinical Features, Complications, and Management
J. Clin. Oncol., January 5, 2000; 18(1): 214 - 214.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 94 - 109.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.